NRXS Share Price Performance
US$7.25
5.30 (271.79%)
3.6% overvalued intrinsic discount
US$7.00
Fair Value
Price US$7.25
AnalystConsensusTarget US$7.00
AnalystLowTarget US$3.00
AnalystHighTarget US$8.00
Fair ValueUS$7.00
Share Pricen/a
NeurAxis, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
NRXS Community Narratives
AN
Fair Value US$7 3.6% overvalued intrinsic discount
New Category 1 CPT Code Will Drive Long-Term Neuromodulation Adoption And Market Expansion
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$3 141.7% overvalued intrinsic discount
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$8 9.4% undervalued intrinsic discount
Bullish View Expects New Category I CPT Code And Coverage Expansion To Transform Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Bullish View Expects New Category I CPT Code And Coverage Expansion To Transform Prospects
Catalysts About NeurAxis NeurAxis develops and commercializes neuromodulation and diagnostic devices such as IB-Stim and RED for pediatric gastrointestinal disorders. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
9.4% undervalued intrinsic discount
Fair Value
Profit Margin
12.91%
Future PE
30.24x
Price in 2029
US$9.99
New Category 1 CPT Code Will Drive Long-Term Neuromodulation Adoption And Market Expansion
Catalysts About NeurAxis NeurAxis develops and commercializes neuromodulation and diagnostic technologies that address chronic gastrointestinal disorders in pediatric and adult patients. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$7
3.6% overvalued intrinsic discount
Fair Value
Profit Margin
12.91%
Future PE
33.51x
Price in 2028
US$8.75
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
Catalysts About NeurAxis NeurAxis develops neuromodulation devices such as IB-Stim and RED to treat functional gastrointestinal disorders in pediatric and adult populations. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
141.7% overvalued intrinsic discount
Fair Value
Profit Margin
0.13%
Future PE
13.15x
Price in 2028
US$0.04
Trending Discussion
Recently Updated Narratives
AN
Bullish View Expects New Category I CPT Code And Coverage Expansion To Transform Prospects
Fair Value: US$8 9.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
New Category 1 CPT Code Will Drive Long-Term Neuromodulation Adoption And Market Expansion
Fair Value: US$7 3.6% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
Fair Value: US$3 141.7% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NeurAxis, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.77
- 84.23%
- -241.37%
- 4.7%
About NRXS
- Founded
- 2011
- Employees
- 24
- CEO
- WebsiteView website
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
